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Abstract Slow walking speed is associated with in-
creased mortality in the elderly, but it is unknown
whether a similar association is present in late midlife.
Our aim was to examine walking speed in late midlife
as a predictor of mortality, as well as factors that may
explain this association. Data are drawn from the
Whitehall II longitudinal cohort study of British civil
servants. The analyses are based on 6,266 participants
(29% women; mean age061 years, SD06) for whom
“walking speed at usual pace” was measured over 8 ft
(2.44 m) at baseline. Participants were followed for
all-cause and cause-specific mortalities during a mean
of 6.4 (SD00.8) years. During this period, 227 partic-
ipants died. Participants in the bottom sex-specific third
of walking speed (men, <1.26 m/s; women, <1.09 m/s)
had an increased risk of death compared to those in the
middle and top thirds (age- and sex-adjusted hazard
ratio01.89, 95% confidence interval (CI)01.45–2.46),
with no evidence of effect modification by age or sex
(interactions, P≥0.40). The association between walk-
ing speed and mortality was partially explained by base-
line inflammatory markers (percentage reduction of the
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association 22.8%), height and body mass index
(16.6%), chronic diseases (14.0%), and health behaviors
(13.4%). Together these and other baseline factors (so-
cioeconomic status, cardiovascular risk factors, cogni-
tive function) explained 48.5% of the association
(adjusted hazard ratio01.39, 95% CI01.04–1.84). In
conclusion, walking speed measured in late midlife
seems to be an important marker of mortality risk;
multiple factors, in particular inflammatory markers,
partially explain this association.
Keywords Walking speed .Mortality . Inflammation .
Cohort study . Epidemiology
Introduction
Lower walking speed in the elderly has been associat-
ed with increased all-cause (Cooper et al. 2010) and
cardiovascular mortalities (Dumurgier et al. 2009). In
a recent pooled analysis of nine US cohorts, the hazard
ratio for death per 0.1-m/s increase in walking speed
was 0.88 (95% confidence interval (CI)00.87–0.90).
The authors concluded that walking speed may be a
simple and accessible indicator of the health of elderly
people (Studenski et al. 2011); mean age of partici-
pants at baseline in these studies varied between 72
and 79 years. Another recent meta-analysis highlight-
ed the lack of studies that measured walking speed in
younger populations with subsequent follow-up for
mortality (Cooper et al. 2010). It is therefore unknown
whether walking speed at earlier ages is associated
with mortality—as it is in older age groups. Moreover,
very few studies have examined factors that may ex-
plain the association between slower walking speed
and mortality. Elucidating pathways that link worse
physical performances to mortality may help to define
potential new intervention strategies (Cooper et al.
2010).
The objectives of the current investigation were
twofold. First, using the data from the Whitehall II
cohort study, we examined whether walking speed
measured in late midlife is associated with mortality.
Second, in order to improve understanding of the
potential underlying pathways linking walking speed
and mortality, we assessed the contributions of a wide
range of covariates, including sociodemographic and
clinical factors, chronic conditions, cognition, health
behaviors, and inflammatory markers.
Methods
Participants
The Whitehall II cohort study, established in 1985, is a
longitudinal study of 10,308 civil servants (Marmot et
al. 1991). All civil servants aged 35–55 years in 20
London-based departments were invited to participate
(participation rate, 73%). The baseline examination
(phase 1, 1985–1988) included a clinical examination
and a self-administered questionnaire. Subsequent
phases have alternated between postal questionnaires
alone (phases 2 (1988–90), 4 (1995–6), 6 (2001), and
8 (2006)) or accompanied by a clinical examination
(phases 3 (1991–3), 5 (1997–9), 7 (2002–4), and 9
(2007–9)). Participants gave a written consent, and the
study was approved by the University College London
Ethics Committee.
Walking speed
Walking speed was measured at phase 7 (2002–4) over
a clearly marked 8-ft (2.44 m) walking course using a
standardized protocol (Brunner et al. 2009). Partici-
pants were asked to “walk to the other end of the
course at your usual walking pace, just as if you were
walking down the street to go the shops. Walk all the
way past the other end of the tape before you stop.”
The starting position was standing at the start of the
course. A trained nurse walked behind the participant
and stopped timing when the participant’s foot hits the
floor after the end of the walking course. Three tests
were conducted, and the fastest measure was used in
the analysis.
Mortality
A total of 10,297 respondents (99.9%) were traced
for mortality through the national mortality register
(National Health Services Central Registry) using
the National Health Service identification number
assigned to British citizens. Our analyses are based
on deaths that occurred between phase 7 (2002–4)
and January 31st, 2010. We examined all-cause,
cardiovascular, and cancer mortalities; international
classification of disease (ICD) codes identified
cancer (ICD-9, 140.0–209.9; ICD-10, C00–C97)
and cardiovascular (ICD-9, 390.0–458.9; ICD-10,
I00–I99) deaths.
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Covariates
Sociodemographic variables included age, sex, and
socioeconomic status (SES) (based on 6-level British
civil service employment grade at phase 7, which is
related to salary, social status, and level of responsibility
(Marmot et al. 1991).
Health behaviors were drawn from questionnaires
(phases 1, 3, 5, and 7). Smoking history was assessed
using questions on smoking status and current amount
of tobacco smoked categorized as “current smoker at
phase 7,” “recent ex-smoker” (stopped smoking be-
tween phases 1–7), “long-term ex-smoker” (stopped
smoking before phase 1), and “never smoker.” Alcohol
consumption was assessed via questions on the number
of alcoholic drinks (“measures” of spirits, “glasses” of
wine, and “pints” of beer) consumed in the last 7 days at
each phase. This was converted to number of units
(1 unit08 g) of alcohol. The frequency of fruit and
vegetable consumption was assessed on an eight-point
scale (ranging from “seldom or never” to “two or more
times a day”). The number of hours of moderate and
vigorous physical activity per week was calculated from
a question on the number of hours of physical activity at
different levels (phases 1 and 3) and from a 20-item
questionnaire on frequency and duration of participation
in walking, cycling, sports, gardening, housework, and
home maintenance (phases 5 and 7) (Sabia et al. 2009).
Summary measures of health behaviors over the four
phases were used in the analyses: smoking history as
defined above and mean values over four phases for
other health behaviors.
Body mass index (BMI) was calculated as weight
divided by height squared (kg/m²) measured at phase 7
clinical examination (Sabia et al. 2010), and catego-
rized as <20, 20.0–24.9, 25–29.9, and ≥30 kg/m2.
Cardiovascular risk factors included serum total
cholesterol and systolic/diastolic blood pressure
(phases 1, 3, 5, and 7) (Sabia et al. 2010). The mean
of four measures (phases 1, 3, 5, and 7) reflected the
history of these risk factors in the analysis. Heart rate
(bpm, beats/minute) was measured at phase 7 via an
electrocardiogram on participants in the supine position
and was categorized for the analysis (<60, 60–80,
and >80 bpm) (Fuster et al. 2001).
Chronic conditions included prevalence until phase
7 of coronary heart disease (CHD), stroke, arthritis,
respiratory illness, diabetes, and depression. CHD
(myocardial infarction, definite angina) was based on
clinically verified events (Ferrie et al. 2006). Stroke,
arthritis, and respiratory illness were assessed through
self-reports. Diabetes was defined by a fasting glucose
≥7.0 mmol/L or a 2-h postload glucose ≥11.1 mmol/L
or a reported doctor-diagnosed diabetes, or by the use
of diabetes medication (Expert committee on the di-
agnosis and classification of diabetes mellitus 2003).
Self-report on the use of antidepressant drugs in the
14 days preceding phase 7 was included as an indica-
tor of current depression; depressive symptoms in the
last 7 days at phase 7 were assessed using the Center
for Epidemiologic Studies Depression (CES-D) scale.
Use of NSAIDs was assessed in a similar manner.
Forced vital capacity and FEV1 were measured at
phase 7 using a portable flow spirometer in a subset
of participants (Sabia et al. 2010).
Inflammatory markers (interleukin-6, IL-6; C-
reactive protein, CRP) were measured at phases 3 and
7 (Sabia et al. 2010; Elovainio et al. 2010). As their
distributions were skewed, they were log-transformed
for the analysis, and the mean of two measures were
used in the analysis.
Cognitive status was assessed at phase 7 using a
test of reasoning (Alice Heim 4-I, AH4-I); higher
scores correspond to better function (Heim 1970).
Statistical analysis
Analyses were undertaken using STATA 10 (StataCorp
LP, TX, USA) and SAS 9.1 (SAS Institute, NC, USA).
Descriptive statistics were used to examine participants’
characteristics as a function of vital status and tertiles of
walking speed. As men walked faster than women,
walking speed was categorized using sex-specific ter-
tiles, and these groups were compared using linear or
logistic regression with adjustment for age and sex.
For the survival analyses, participants were followed-
up until death or until the date of censoring for those
who were alive (date of emigration or January 31st,
2010), whichever occurred first. The cumulative risk of
all-cause death was plotted by tertiles of walking speed
which are defined using sex-specific cutoffs (men <1.26,
1.26–1.45, and >1.45 m/s; women <1.09, 1.09–1.30,
and >1.30 m/s), and the logrank test was used for statis-
tical testing. Cox proportional hazards models with age
as the time axis estimated hazard ratios (HR) and 95%
CI. The proportional hazards assumption was verified
using Schoenfeld residuals. Interactions were tested by
including multiplicative terms in the models.
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Model 1 included walking speed and sex as predic-
tors and was controlled for age by considering it as the
timescale. We examined the extent to which the associ-
ation between walking speed and mortality was attenu-
ated by adding the following covariates (models 2–8):
SES; height and BMI, health behaviors, cardiovascular
risk factors, chronic conditions, cognitive function, and
inflammatory markers. The final model (model 9) in-
cluded all covariates. The percentage reduction (PR) of
the association between walking speed and mortality
attributed to covariates included in model i was calcu-
lated using the formula 100×(βModel 1 − βModel i) /
(βModel 1), where β is the coefficient obtained from the
Cox proportional hazards model.
Results
The analyses were based on 6,266 participants, with
complete data on walking speed and covariates, con-
tributing to a total of 39,892 person-years. Compared
to the baseline of the Whitehall II study (phase 1,
1985–8), those included in the analysis were younger,
more likely to be men, and were from the higher SES
group (P<0.001). Two hundred seventeen participants
examined at phase 7 were not included in the analysis
due to missing walking speed data: these persons
were older (62.0 [SD06.1] vs 61.1 [SD06.0]
years, P00.02), more likely to be women (34.6%
vs 29.0%, P00.08), and were from the lower SES
group (28.6% vs 23.7%, P00.10) than those who
were included. Excluded participants had higher
mortality (6.0% vs 3.6%), but this difference was not
statistically significant after adjustment for age, sex,
and SES (P00.15).
During a mean follow-up of 6.4 (SD00.8, range0
0.2–7.3) years, 227 of the 6,266 participants included
in the analyses died (mortality rate05.7/1,000 person-
years): 111 from cancer (mortality rate02.8/1,000
person-years) and 62 from cardiovascular disease
(mortality rate01.6/1,000 person-years). Table 1 sum-
marizes participants’ characteristics at the start of the
follow-up as a function of vital status at the end of
follow-up. In age- and sex-adjusted analyses, those
who died were older, more likely to be smokers,
consumed more alcohol, exercised less, and had a
higher BMI, heart rate, and levels of inflammatory
markers. They also had a lower cognitive score, walking
speed, and cholesterol level.
Table 2 shows participants’ characteristics by ter-
tiles of walking speed. Mean (SD) walking speed was
higher in men (1.4 [0.3]) than women (1.2 [0.3], P<
0.001). There was a significant linear association be-
tween all other covariates and walking speed, except
for alcohol consumption and history of respiratory
disease. Subjects who walked slower had higher levels
of inflammatory markers (P<0.001). As shown in
Fig. 1, there was also a statistically significant differ-
ence in the cumulative risk of all-cause mortality
across tertiles of walking speed (logrank, P<0.001).
The curves began to separate during the first year of
follow-up and continued to diverge over the follow-up.
Differences in cumulative risk of death were also evi-
dent for cardiovascular (P<0.001) and cancer (P<
0.001) deaths (results not shown).
Cox proportional hazards model adjusted for age and
sex with participants in the top tertile of walking speed
as the reference (men, >1.45 m/s; women, >1.30 m/s)
showed the HR of death to be 1.30 (95%CI00.89–1.92,
P00.18) for participants in the middle tertile (men,
1.26–1.45 m/s; women, 1.09–1.30 m/s) and 2.19 (95%
CI01.54–3.11, P<0.001) for participants in the bottom
(men, <1.26 m/s; women, <1.09 m/s). Because there
was no statistically significant difference between the
top and middle tertiles of walking speed for all-cause (as
well as for cardiovascular and cancer mortalities), further
analyses combined these two groups. In sensitivity anal-
yses, we also modelled walking speed as a continuous
variable (Table S1).
In Table 3, model 1 shows that participants in the
lowest tertile of walking speed had a higher risk of
death (HR01.89 [1.45–2.46]) compared to partici-
pants who walked faster. This association was not
modified by age: the HR was 2.17 (1.04–4.50) for
subjects in the lowest quartile of age (≤56.0 years;
mean age053.9, range050.5–56.0 years) and 2.09
(1.41–3.09) for those in the highest quartile (>66.2 years;
mean age069.2, range066.3–73.9 years) (interaction,
P00.58). The association between walking speed and
mortality was stronger in men (HR02.00 [1.46–2.75])
than women (HR01.68 [1.04–2.71]), but the difference
was not statistically significant (P00.40); therefore, all
analyses combine men and women and are adjusted for
sex and age. SES (model 2), cardiovascular risk factors
(model 5), and cognitive function (model 7) explained a
small part of the walking speed–mortality association
(PR03.3–6.4%). Adjustment for height and BMI
(model 3), health behaviors (model 4), and chronic
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conditions (model 6) led to PRs of a similar mag-
nitude (13.4–16.6%). The highest PR (22.8%) was
on adjustment for inflammatory markers (model 8).
All the covariates together explained nearly half (PR0
48.5%) the association; in the fully adjusted model,
higher IL-6 (P00.04) and CRP (P00.04) remained
associated with mortality. Analyses based on continuous
walking speed yielded similar findings (Table S1).
Analyses for the two main causes of death
(cardiovascular, cancer) are shown as supplemen-
tary results (Table S2). The HR was higher for
cardiovascular (HR02.24 [1.34–3.74]) than for
cancer (HR01.62 [1.11–2.36]) mortality; these
relationships were not modified by age (cardiovas-
cular, P00.54; cancer, P00.99) or sex (cardiovas-
cular, P00.46; cancer, P00.75). For both causes,
Table 1 Characteristics of the study population according to vital status at the end of the follow-up
Characteristics Alive at the end of
follow-up (N=6039)
Dead at the end of
follow-up (N=227)
P valuea
Sociodemographic factors
Age M (SD) 60.9 (5.9) 64.3 (6.1) <0.001
Women N (%) 1746 (28.9) 71 (31.3) 0.60
Low socioeconomic status N (%) 1413 (23.4) 70 (30.4) 0.12
Health behaviors
Current smokers N (%) 478 (7.9) 28 (12.3) 0.004
Units of alcohol/week M (SD) 11.7 (11.7) 12.9 (14.6) 0.008
Frequency of fruit and
vegetable consumption/week
M (SD) 8.0 (3.3) 7.8 (3.4) 0.14
Hours of moderate and vigorous
physical activity/week
M (SD) 3.7 (2.7) 3.0 (2.4) <0.001
Height (cm) M (SD) 171.1 (9.3) 169.1 (9.8) 0.02
BMI (kg/m²) M (SD) 26.7 (4.3) 28.2 (5.2) <0.001
Cardiovascular risk factors
Systolic blood pressure (mmHg) M (SD) 123.4 (12.3) 126.2 (12.6) 0.11
Diastolic blood pressure (mmHg) M (SD) 76.9 (7.9) 77.6 (8.7) 0.50
Total blood cholesterol (mmol/L) M (SD) 6.0 (0.9) 5.9 (1.0) 0.03
Heart rate (beats/min) M (SD) 68.1 (12.1) 70.3 (13.0) 0.009
Chronic conditions
Diabetes N (%) 573 (9.5) 45 (19.8) <0.001
Coronary heart disease N (%) 540 (8.9) 45 (19.8) <0.001
Stroke N (%) 146 (2.4) 16 (7.1) 0.003
History of arthritis N (%) 1569 (26.0) 79 (34.8) 0.22
History of respiratory disease N (%) 802 (13.3) 34 (15.0) 0.43
Anti-depressant use N (%) 208 (3.4) 11 (4.9) 0.20
Cognitive function
AH4-I score M (SD) 43.7 (11.3) 40.1 (12.5) 0.01
Inflammatory markers
CRP (log transformed) (mg/L) M (SD) 0.07 (1.00) 0.54 (1.04) <0.001
IL-6 (log transformed) (pg/mL) M (SD) 0.53 (0.54) 0.81 (0.61) <0.001
Walking speed (m/s) M (SD) 1.3 (0.3) 1.2 (0.3) <0.001
End of follow-up was defined as January 31st, 2010 or date of censoring, whichever occurred first
M mean, SD standard deviation
a Calculated using analysis of covariance for continuous variables and logistic regression for categorical variables; P values are adjusted
for age and sex
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adjustment for inflammatory markers led to an impor-
tant reduction in HRs (cardiovascular, PR023.4%; can-
cer, PR021.2), and all the covariates explained nearly
half of the association (cardiovascular, PR049.3%; can-
cer, PR048.2%). Analyses based on continuous walk-
ing speed yielded similar findings (Table S1).
In sensitivity analyses, we excluded deaths occurring
within the first 2 years of follow-up (N044); the asso-
ciation between walking speed and mortality remained
unchanged for all-cause (HR01.80 [1.34–2.42]). Car-
diovascular (HR01.99 [1.13–3.51]) and cancer mortal-
ities (HR01.51 [0.98–2.31) in analyses were adjusted
Table 2 Characteristics of the study population according to tertiles of walking speed
Characteristics Sex-specific tertiles of walking speeda P valueb
Top (N=2,065) Middle (N=2,093) Bottom (N=2,108)
Sociodemographic factors
Age M (SD) 59.8 (5.6) 60.7 (5.9) 62.7 (6.0) <0.001
Women N (%) 604 (29.3) 573 (27.4) 640 (30.4) <0.001
Low socioeconomic status N (%) 330 (16.0) 449 (21.5) 704 (33.4) <0.001
Health behaviors
Current smokers N (%) 127 (6.2) 173 (8.3) 206 (9.8) <0.001
Units of alcohol/week M (SD) 11.9 (11.5) 12.0 (11.7) 11.2 (12.4) 0.18
Frequency of fruit and vegetable
consumption/week
M (SD) 8.6 (3.2) 8.0 (3.2) 7.4 (3.2) <0.001
Hours of moderate and vigorous
physical activity/week
M (SD) 3.8 (2.6) 3.8 (2.7) 3.4 (2.6) <0.001
Height (cm) M (SD) 172.0 (8.7) 171.6 (9.3) 169.6 (9.6) <0.001
BMI (kg/m²) M (SD) 26.0 (3.9) 26.5 (4.1) 27.7 (4.9) <0.001
Cardiovascular risk factors
Systolic blood pressure (mmHg) M (SD) 122.2 (12.3) 123.3 (12.1) 124.9 (12.4) <0.001
Diastolic blood pressure (mmHg) M (SD) 76.3 (8.0) 76.8 (7.9) 77.5 (7.8) <0.001
Total blood cholesterol (mmol/L) M (SD) 5.9 (0.9) 6.0 (0.9) 6.1 (0.9) 0.05
Heart rate (beats/min) M (SD) 67.5 (11.9) 68.6 (12.2) 68.4 (12.4) <0.001
Chronic conditions
Diabetes N (%) 126 (6.1) 197 (9.4) 295 (14.0) <0.001
Coronary heart disease N (%) 143 (6.9) 174 (8.3) 268 (12.7) <0.001
Stroke N (%) 39 (1.9) 38 (1.8) 85 (4.0) 0.002
History of arthritis N (%) 461 (22.3) 486 (23.2) 701 (33.3) <0.001
History of respiratory disease N (%) 276 (13.4) 276 (13.2) 284 (13.5) 0.23
Antidepressant use N (%) 55 (2.6) 69 (3.3) 95 (4.6) <0.001
Cognitive function
AH4-I score M (SD) 46.4 (9.8) 44.3 (10.9) 39.9 (12.3) <0.001
Inflammatory markers
CRP (log transformed) (mg/L) M (SD) −0.09 (0.99) 0.04 (0.98) 0.32 (1.00) <0.001
IL-6 (log transformed) (pg/mL) M (SD) 0.45 (0.52) 0.51 (0.53) 0.65 (0.58) <0.001
Death at the end of the follow-up N (%) 44 (2.1) 62 (3.0) 121 (5.7) <0.001
M mean, SD standard deviation
a Based on cutoffs defined by tertiles of the distribution of walking speed in men and women: <1.26, 1.26–1.45, and >1.45 m/s in men; <1.09,
1.09–1.30, and >1.30 m/s in women
b Percentages of categorical variables and means of continuous variables are presented by tertiles of walking speed for clarity; walking
speed was considered as the dependent variable in linear regression models to compute P values. P values are adjusted for age and sex
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for age and sex. When we excluded subjects with a
history of CHD, stroke, or diabetes at baseline (N0
1,194), the age and sex adjusted HR for all-cause (1.76
[1.26–2.45]) and cardiovascular mortalities (1.85 [0.90–
3.79]) decreased, but adjustment for inflammatory
markers still led to an important attenuation of the
association (all-cause, PR025.3%; cardiovascular,
PR029.9%). Using CES-D score rather than antidepres-
sant use as a surrogate for depression, adjustment for
forced expiratory volume/height² instead of history of
respiratory disease, exclusion of NSAIDs users (N0
320), or participants with CRP level greater than 10 g/L
(N0103) on the day of examination led to conclusions
similar to those in main analyses.
Fig. 1 Cumulative risk of
all-cause death according
to sex-specific tertiles of
walking speed (dashed line,
top; dotted line, middle;
solid line, bottom) (logrank,
P<0.001). The sex-specific
cutoffs were <1.26
(N01,461), 1.26–1.45
(N01,520), and >1.45 m/s
(N01,468) in men; <1.09
(N0604), 1.09–1.30
(N0573), and >1.30 m/s
(N0640) in women
Table 3 Hazard ratios for all-cause mortality according to walking speed (bottom tertile vs middle and top tertiles combined)
All-cause mortality
N deaths / N 227/6,266
Adjustment HRa 95% CI %Δ
Model 1: adjusted for age and sex 1.89 1.45–2.46 –
Model 2: model 1 + socioeconomic status 1.85 1.41–2.42 3.3
Model 3: model 1 + height + BMI 1.70 1.29–2.23 16.6
Model 4: model 1 + health behaviorsb 1.73 1.32–2.27 13.4
Model 5: model 1 + cardiovascular risk factorsc 1.86 1.42–2.42 2.7
Model 6: model 1 + chronic conditionsd 1.73 1.32–2.26 14.0
Model 7: model 1 + cognitive functione 1.81 1.38–2.38 6.4
Model 8: model 1 + inflammatory markersf 1.63 1.25–2.14 22.8
Model 9: fully adjusted 1.39 1.04–1.84 48.5
a HR computed using Cox proportional hazards models with age as the time axis for participants in the bottom tertile of walking speed
(<1.26 m/s in men, <1.09 m/s in women) compared to participants in the top and middle tertiles combined. The assumption of
proportionality of hazards was verified (P00.39). The percentage reduction (%Δ) of the association between walking speed and
mortality attributed to covariates included in model i was calculated using the formula 100×(βModel 1 − βModel i) / (βModel 1), where β is
the regression coefficient obtained from the Cox proportional hazards model
b Smoking history, alcohol consumption, physical activity, and fruit and vegetable consumption
c Systolic and diastolic blood pressure, blood cholesterol, and heart rate
d History of diabetes, coronary heart disease, self-reported stroke, arthritis, respiratory diseases, and antidepressant use at phase 7
e AH4-I test
f Interleukin-6 and C-reactive protein (log-transformed)
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Discussion
In the Whitehall II cohort study, walking speed was
assessed in late midlife, and persons who walked slower
had an increased risk of dying during a mean follow-up
of 6.4 years. This relationship was also observed for the
two main causes of death (cardiovascular and cancer)
and was present in all age groups. Among a large
number of covariates, inflammatory markers, and, to a
lesser extent, chronic diseases, health behaviors, and
height and BMI contributed to this association.
Several studies have shown that slower walking
speed is associated with increased mortality (Cooper
et al. 2010; Studenski et al. 2011). However, all of
them measured walking speed in elderly subjects. To
our knowledge, this is the first study to have examined
whether this association is present when walking
speed is measured in late midlife. We measured walking
speed at a median age of 60 years, i.e., over 10 years
earlier than previous studies (Cooper et al. 2010). In a
recent pooled analysis of nine US cohorts, the mean age
of the participants was comprised between 71.8 and
78.9 years; baseline walking speed was comprised
between 0.56 and 1.19 m/s and was therefore
markedly slower than in the present study (Studenski
et al. 2011). Although participants from our study were
younger than those from previous studies and thus
walked faster, the HR for death per 0.1-m/s increase in
walking speed was remarkably similar in the pooled
analysis (HR00.88) and in our study (HR00.87). These
findings suggest that walking speed can also be consid-
ered as a simple and accessible indicator of health in late
midlife.
The factors that statistically explain the association
between walking speed and mortality include confound-
ers, common causes, and mediators and are likely to be
complex. We examined the role of covariates primarily
to highlight their role as “common causes.” A previous
study, in which walking speed was measured in subjects
aged 65–85 years, reported that walking speed was more
strongly associated with cardiovascular than cancer
deaths, which suggests that cardiovascular risk factors
and diseases play a role (Dumurgier et al. 2009). In
agreement with this hypothesis, we found that diabetes,
stroke, and CHD—which were associated with slower
walking speed and mortality—attenuated the associa-
tion, in particular for cardiovascular mortality. On the
other hand, cardiovascular risk factors, such as blood
pressure, cholesterol, and heart rate made a modest
contribution.
The most important contributing factors to the as-
sociation between walking speed and mortality were
inflammatory markers; their role was also apparent
after excluding participants with stroke, CHD, or dia-
betes. Elevated inflammatory markers are associated
with a wide range of conditions, including clinical and
subclinical cardiovascular disease (Ridker et al. 2000a;
Ridker et al. 2000b; Rodondi et al. 2010), diabetes,
pulmonary disease, and chronic kidney disease, many
of which are mortality risk factors (Chang et al. 2010).
There is also an evidence to suggest that chronic inflam-
mation represents a feature of the aging process itself
(Franceschi et al. 2007). Inflammatory markers are as-
sociated in elderly subjects with a wide range of out-
comes, including disability (Kuo et al. 2006), worse
motor performances (Hsu et al. 2009), frailty (Leng et
al. 2007), and death (Cappola et al. 2003). Our study
extends this evidence by showing (1) that inflammatory
markers are cross-sectionally associated with worse
physical performance in late midlife and (2) that
inflammatory markers explain a significant part of
the association between walking speed and mortality,
even in the absence of overt cardiovascular disease.
Inflammatory markers may reflect subclinical cerebro-
vascular disease (Rosenberg 2009; Yoshida et al. 2009;
Yoshida et al. 2010), which is associated with worse
clinical performances (Soumaré et al. 2009) and mortal-
ity (Bokura et al. 2006; Ikram et al. 2009). Decreased
muscle strength has been linked to inflammation
(Degens 2010) and mortality (Landi et al. 2010;
Newman et al. 2006) and may represent another possi-
ble pathway. Our findings suggest that inflammatory
mechanisms associated with adverse outcomes in elderly
subjects may be at play many years earlier; this observa-
tion has important implications because it may help to
better define the time period that should be the target of
preventive interventions.
Persons who walked slower had an increased risk
of dying from cancer in our study, but a corresponding
association has not been observed in a previous study
on elderly persons (Dumurgier et al. 2009). Reasons
for this discrepancy are unclear but may be related to
differences in the types of cancer or age of the partic-
ipants. In the present study, health behaviors played a
stronger role than chronic conditions in explaining the
association. Inflammatory markers also attenuated the
950 AGE (2013) 35:943–952
association between walking speed and cancer mortali-
ty; however, they did not remain associated with cancer
mortality in the fully adjusted model, thus suggesting
that their effect was explained by other covariates.
Main strengths of this study include a standardized
objective measure of motor performances in late midlife
and the assessment of a wide range of covariates over a
15-year period preceding the walking speed measure.
Short-distance walking speed has been measured in dif-
ferent studies over different distances (usually comprised
between 2 and 10 m) (Graham et al. 2008; Studenski et
al. 2011); wemeasuredwalking speed over 8 ft, but it has
been shown that these measures are highly correlated
and predict mortality in a similar way (Studenski et al.
2011). A limitation of our study is that white-collar civil
servants are not representative of the general population;
the sample, however, covered a wide socioeconomic
range (Marmot et al. 1991). As our analyses are based
on participants who took part in phase 7 of a longitudi-
nal study, we did not include subjects who died earlier
and a small number of subjects for whomwalking speed
was not measured. Finally, for cause-specific mortality,
our analyses are based on small numbers of events.
Despite these limitations, our findings provide a
strong evidence to suggest that slow walking speed
during late midlife is associated with increased mor-
tality over 6 years of follow-up and thus may be a
good marker of general health in late midlife. Our
results also emphasize the importance of inflammatory
markers in explaining this association.
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